Reviva Pharmaceuticals Files 8-K
Ticker: RVPH · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001742927
| Field | Detail |
|---|---|
| Company | Reviva Pharmaceuticals Holdings, Inc. (RVPH) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k
TL;DR
Reviva Pharma dropped its Q1 2026 8-K. Check financials.
AI Summary
Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the primary document being the 8-K itself, filed in iXBRL format.
Why It Matters
This 8-K filing provides crucial updates on Reviva Pharmaceuticals' financial performance and operational status, which is essential for investors and stakeholders to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not indicate any unusual or significant risks.
Key Players & Entities
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Filer
- 0001742927 (company) — CIK Number
- 2026-03-30 (date) — Filing Date
FAQ
What specific financial information is being reported in this 8-K filing?
This 8-K filing reports on the 'Results of Operations and Financial Condition' as per Item 2.02.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 30, 2026.
What are the main document types included in this filing?
The main document types include the FORM 8-K in iXBRL format, an exhibit (EX-99.1), and the complete submission text file.
What is the CIK number for Reviva Pharmaceuticals Holdings, Inc.?
The CIK number for Reviva Pharmaceuticals Holdings, Inc. is 0001742927.
What is the business address of Reviva Pharmaceuticals Holdings, Inc.?
The business address is 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2026-03-30 06:11:59
Key Financial Figures
- $0.0001 — registered Common Stock , par value $0.0001 per share RVPH Nasdaq Capital Market
Filing Documents
- rvph20260313_8k.htm (8-K) — 29KB
- ex_937921.htm (EX-99.1) — 122KB
- 0001437749-26-010140.txt ( ) — 294KB
- rvph-20260330.xsd (EX-101.SCH) — 3KB
- rvph-20260330_def.xml (EX-101.DEF) — 12KB
- rvph-20260330_lab.xml (EX-101.LAB) — 15KB
- rvph-20260330_pre.xml (EX-101.PRE) — 12KB
- rvph20260313_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the "Company") issued a press release on March 30, 2026, disclosing financial information and operating metrics for its fiscal year ended December 31, 2025 and discussing its business outlook. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01
Item 7.01. Regulation FD Disclosure. See "Item 2.02 Results of Operations and Financial Condition" above. The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated March 30, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Dated: March 30, 2026 By: /s/ Narayan Prabhu Name: Title: Narayan Prabhu Chief Financial Officer